MedTrace Logo

Pharmacogenomic Testing Of the Elderly To Reduce Morbidity

NCT02095769 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 280000

Last updated 2015-02-24

No results posted yet for this study

Summary

The goal of the POETRY Registry is to determine whether data from Pharmacogenomic (PGx) Testing for elderly and disabled patients can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug events, hospitalizations, and emergency department visits.

The way an individual processes or metabolizes a drug is in part determined by their genes, and there is known to be genetic variation from one human to another. The study of the way in which genes affect an individual's response to drugs is known as "Pharmacogenomics."

Conditions

  • Genetics of Drug Metabolism

Sponsors & Collaborators

  • Syntactx

    collaborator NETWORK

  • General Genetics Corporation

    lead INDUSTRY

Principal Investigators

  • Bill Massey, PhD · Northwestern University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02095769 on ClinicalTrials.gov